| Submit your comments on this article |
| Science & Technology |
| Doomberg - Survival as a Service |
| 2024-05-31 |
| [Doomberg] "Medicine rests upon four pillars — philosophy, astronomy, alchemy, and ethics." — Paracelsus Nathan Vardi’s gripping book For Blood and Money: Billionaires, Biotech, and the Quest for a Blockbuster Drug tells the story of the discovery and commercialization of Ibrutinib, the breakthrough blood cancer drug. Originally synthesized by Celera Genomics as a tool compound for the study of an important enzyme in cancer cell survival and proliferation pathways (Bruton's tyrosine kinase (BTK)), Ibrutinib was scooped up by the tiny firm Pharmacyclics for a relative pittance. Less than a decade later, pharmaceutical giant AbbVie outbid Johnson & Johnson to acquire Pharmacyclics for the incredible sum of $21 billion. The driving force behind Ibrutinib’s meteoric rise was entrepreneur Robert Duggan, whose son had died of brain cancer at the age of 26. Despite having no prior experience in the field of oncology, a deeply motivated Duggan accumulated stock in Pharmacyclics with a sizeable personal investment, installed himself as CEO and Chair, and managed the company with what former employees would later characterize as ruthless efficiency. Many of the early patients receiving Ibrutinib suffered from chronic blood cancers and had already received several rounds of toxic chemotherapy and other risky treatments. Some were near death and out of viable options. When such patients showed stunning results in just a matter of weeks with barely any negative side effects—some even walking out of the hospital feeling normal again—Duggan knew he had a winner on his hands. He would go on to move mountains to get the drug to market as swiftly as possible before selling the company. Duggan personally netted $3.5 billion in proceeds from the AbbVie transaction. Although no form of blood cancer cracks the top ten in global incidence rates, hematological oncology receives outsized attention from scientists and investors alike. The nature of blood cancer is such that the field effectively represents the front line of combat in the war on cancer more broadly. Since blood cancer cells circulate in the bloodstream or accumulate in accessible tissues like lymph nodes, directly targeting them with medication is a far simpler task than reaching cells buried deep within solid tumors. Further, patients can be readily sampled for monitoring with minimal invasiveness—a few milliliters of blood drawn from a needle can lead to scores of sophisticated, rapid analyses. This also facilitates personalization of care, as the genetic profile of an individual’s cancer can be monitored through the disease’s progression. Perhaps most importantly, discoveries in blood cancer research often apply to other forms of cancer, making the size of the potential prize far greater than the narrow addressable market of the proving ground. |
| Posted by:Besoeker |
| #2 There's already too much intervention. |
| Posted by: Skidmark 2024-05-31 10:04 |
| #1 |
| Posted by: Besoeker 2024-05-31 07:15 |